

REMARKS**I. Claim Status**

Claims 1-57 are pending.

II. Election/Restriction

Restriction to one of the following inventions was required under 35 U.S.C. § 121:

- I. Claim 11, drawn to a method for the treatment, prevention, or inhibition of a CMS disorder, pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition, comprising administering 6-[[5-(4-chlorobenzoyl)-1,4-dimethyl- 1H-pyrrol-2-yl]methyl]-3(2 H)-pyridazinone or a prodrug thereof and reboxetine, classified in class 570, subclass 182.
- II. Claim 12-21, drawn to a method for the treatment, prevention, or inhibition of a CNS disorder, pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition, comprising administering the recited Cox-2 selective inhibitors in claims 12-21 or prodrugs thereof and reboxetine, classified in class 546 and 549.
- III. Claim 24, drawn to a method for the treatment, prevention, or inhibition of a CNS disorder, pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition, comprising administering the recited Cox-2 selective inhibitors recited in claim 24 or prodrugs thereof and reboxetine, classified in class 540-549.
- IV. Claim 25, drawn to a method for the treatment, prevention, or inhibition of a CMS disorder, pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition, comprising administering the recited Cox-2 selective inhibitors recited in claim 25 or prodrugs thereof and reboxetine, classified in class 548, subclass 240
- V. Claim 26, drawn to a method for the treatment, prevention, or inhibition of a CMS disorder, pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition, comprising administering the recited Cox-2 selective inhibitors recited in claim 26 or prodrugs thereof and reboxetine, classified in class 544, and subclass 224
- VI. Claim 27-28, drawn to a method for the treatment, prevention, or inhibition of a CMS disorder, pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition, comprising administering the recited Cox-2 selective inhibitors recited in claims 27-28 or prodrugs thereof and reboxetine, classified in class 544, subclass 224
- VII. Claim 29-30, drawn to a method for the treatment, prevention, or inhibition of a CMS disorder, pain and inflammation, or an inflammation-associated disorder in a subject in need of such treatment, prevention, or inhibition, comprising

administering the recited Cox-2 selective inhibitors recited in claim 29-30 or prodrugs thereof and reboxetine, classified in class 570, subclass 310.

Applicants elect the invention of Group VI, claims 27-28, for prosecution purposes, without traverse. Applicants were also required to make an election of a single disclosed COX-2 selective inhibitor and a reboxetine. Applicants hereby elect celecoxib. Applicants where further required to make an election of a single disclosed species of disease. Applicants hereby elect pain as the single disclosed species of disease.

Claims 1-10, 27-28, 31-49, 51, and 53-57 are readable upon the elected group and species.

III. Conclusion

The application is now in condition for allowance, which allowance is respectfully solicited.

Dated: 2/27/07

Respectfully submitted,



David R. Kurlandsky
Registration No. 41,505
Pfizer Inc
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-7304
Facsimile: (734) 622-1553